Home \| About Us \| Investors \| Careers \| Contact Us

Home | Medical Professionals | AMS Medical Solutions

Overview

The UroLume^® Urethral Stent is used to relieve urinary obstructions secondary to benign prostatic hyperplasia (BPH), recurrent bulbar urethral strictures (RBUS), or detrusor external sphincter dyssynergia (DESD). In this section, we will cover its use as a prostate health solution for treating BPH.

For details about its other applications, click here for Strictures or here for DESD.

Features
UroLume is a braided mesh cylinder made of high strength, impact grade, super alloy wire. It has the potential to expand to a diameter of 14 mm (42F) and is available in lengths of 1.5 cm, 2.0 cm, 2.5 cm and 3.0 cm (also available in 3.5 and 4.0 length in international markets).

The braided mesh is designed to expand radially, applying constant gentle pressure to hold open the sections of the urethra that obstruct the flow or urine. The open, diamond-shape cell design of the stent allows the stent to eventually become embedded in the urethra, thus minimizing the risk for encrustation and migration.

UroLume is provided preloaded in a sterile, disposable delivery instrument. The outer diameter of the tool is 22F along the shaft and 24 F at the tapered tip. The delivery instrument provides:

Secure housing for the stent to allow for transurethral placement
Direct visualization of the stent and the urethra throughout the procedure
The ability for you to deploy the stent accurately within the urethra

Benefits
UroLume offers a number of benefits for your patients with BPH:

Quick and immediate obstruction relief to the prostatic urethra¹
Increased post-procedural patient comfort, because most patients don't require catheterization¹
Tissue in-growth ensures anchorability of the stent in the urethra and reducing risk of migration
12 years of clinical follow-up demonstrates safety and efficacy²

1. Tekchandani AH, Oesterling JE. The UroLume endoprosthesis: indications, placements, and results. Cotemporary Urology Oct 1996 (no pages listed).
2. Masood S, Djaladat H, Kouriefs C, Keen M, Palmer JH. The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int Dec. 2004 v. 94(9)p. 1271-4.

600082-01A (12/07)